Join
Live feed
·
PRReleasevia Quantisnow
Vaccinex Inc. logo

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
VCNX· Vaccinex Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VCNX (Vaccinex Inc.) and more on Quantisnow.